BioCryst Pharmaceuticals, Inc. (BCRX)
收市後：
| 前收市價 | 7.16 |
| 開市 | 7.21 |
| 買盤 | 7.15 x 2900 |
| 賣出價 | 7.37 x 1300 |
| 今日波幅 | 7.07 - 7.37 |
| 52 週波幅 | 6.62 - 14.50 |
| 成交量 | |
| 平均成交量 | 2,516,530 |
| 市值 | 1.393B |
| Beta 值 (5 年，每月) | 1.88 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.30 |
| 業績公佈日 | 2023年10月30日 - 2023年11月03日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 15.20 |
Insider MonkeyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call Transcript August 3, 2023 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.25. Operator: Good morning and welcome to the BioCryst Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn […]
Insider MonkeyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript February 21, 2023 Operator: Good morning and welcome to the BioCryst Fourth Quarter 2022 Earnings Conference Call. Please note this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead. John Bluth: Thanks, Andrea. Good […]
BenzingaAnalyst Sees Attractive Entry Opportunity After BioCryst's Pipeline Setback
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study. The company noted recent dose-related observations in an ongoing BCX10013 nonclinical study would delay the clinical program. BioCryst planned to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria (PNH), to evaluate once-daily dosing. In January, the company announced initial data from ongoing pha
